Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Evoke Pharma (EVOK) Return on Capital Employed (2021 - 2025)

Historic Return on Capital Employed for Evoke Pharma (EVOK) over the last 5 years, with Q3 2025 value amounting to 1.44%.

  • Evoke Pharma's Return on Capital Employed rose 3100.0% to 1.44% in Q3 2025 from the same period last year, while for Sep 2025 it was 1.44%, marking a year-over-year increase of 3100.0%. This contributed to the annual value of 2.72% for FY2024, which is 422300.0% down from last year.
  • According to the latest figures from Q3 2025, Evoke Pharma's Return on Capital Employed is 1.44%, which was up 3100.0% from 1.16% recorded in Q2 2025.
  • In the past 5 years, Evoke Pharma's Return on Capital Employed registered a high of 23.36% during Q3 2023, and its lowest value of 8.42% during Q1 2024.
  • For the 5-year period, Evoke Pharma's Return on Capital Employed averaged around 0.25%, with its median value being 0.85% (2023).
  • Per our database at Business Quant, Evoke Pharma's Return on Capital Employed surged by 240000bps in 2023 and then tumbled by -251100bps in 2024.
  • Evoke Pharma's Return on Capital Employed (Quarter) stood at 0.84% in 2021, then rose by 16bps to 0.71% in 2022, then surged by 579bps to 3.4% in 2023, then tumbled by -128bps to 0.95% in 2024, then crashed by -51bps to 1.44% in 2025.
  • Its last three reported values are 1.44% in Q3 2025, 1.16% for Q2 2025, and 0.77% during Q1 2025.